Semaglutide Eligibility Could Expand Significantly with New Liver Disease Indication
Background
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Non-Alcoholic Steatohepatitis (NASH), is a severe form of fatty liver disease characterized by inflammation and liver cell damage, often progressing to fibrosis and cirrhosis. It is strongly associated with obesity and type 2 diabetes, for which semaglutide is already approved. However, the potential impact of fibrotic MASH as a new indication on semaglutide eligibility in the broader US adult population remains unquantified.
Results
The study projected a significant expansion of semaglutide eligibility across the US adult population. If fibrotic MASH becomes an approved indication, an additional 15.7 million US adults could become eligible for semaglutide, representing a 35% increase over current eligibility based on type 2 diabetes or obesity. Specifically, this newly eligible group would include 8.2 million individuals with stage F2/F3 fibrosis and 7.5 million with cirrhosis (F4), indicating advanced liver disease. The analysis further revealed that 60% of these newly eligible individuals would not have qualified for semaglutide under its current type 2 diabetes or obesity indications, highlighting a distinct, underserved population. This expansion would increase the total eligible population from an estimated 45 million to 60.7 million adults.
Why It Matters
This study underscores the immense public health implications of expanding semaglutide indications to include fibrotic MASH. It identifies a large, distinct, and currently underserved population with severe liver disease who could potentially benefit from this therapeutic option, offering a new avenue for disease management beyond existing treatments. The findings provide critical data for regulatory bodies and pharmaceutical companies, suggesting a strong rationale to accelerate clinical trials and regulatory approval processes for semaglutide in MASH. This could pave the way for a new standard of care, significantly impacting the progression of liver disease in millions.